



IBD-BIRD Session

Scientific Group: IBD-BIRD

Day: 31/01-1/02, 2024

Wednesday January 31, 2024

Session 1: **Prime time for AI and advanced imaging in (IBD) endoscopy?**

Moderators: Peter Bossuyt (Imelda), João Sabino (UZ Leuven)

14:00 **Invited Lecture:** Improving histo-endoscopic assessments using artificial intelligence.
Raf Bisschops (UZ Leuven)

14:25 **156 I 01** **Histo-endoscopic remission (HEMR) Predicts Future Relapse in Patients with Ulcerative Colitis and is Associated with Lower Colectomy Risk.**
M. LENFANT (1), G. DE HERTOOGH (2), J. SABINO (1), B. VERSTOCKT (1), M. FERRANTE (1), S. VERMEIRE (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology and Hepatology, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Pathology

14:35 **112 I 02** **Genetic determinants for smoking behaviour improve our understanding of sporadic versus familial Inflammatory Bowel Disease.**
D. JANS (1), Y. ABAKKOUY (1), S. BECELAERE (1), S. VERSTOCKT (2), S. VERMEIRE (3), I. CLEYNEN (1) / [1] KUL - University of Leuven, Leuven, Belgium, Department of Human Genetics, [2] KUL – University of Leuven, Leuven, Belgium, Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), [3] KUL – University of Leuven, Leuven, Belgium, Department of Chronic Disease, Metabolism and Ageing (CHROMETA)

14:45 **18 I 03** **The role of histology for the prediction of clinical relapse in Crohn's disease: A substudy of the STORI cohort.**
C. REENAERS (1), D. ENEA (2), M. NACHURY (3), D. LAHARIE (4), Y. BOUHNİK (5), M. FUMERY (6), J. GORNET (7), A. AURÉLIEN (8), A. ROMAIN (9), M. DE VOS (10), P. MARTEAU (11), A. BOURREILLE (12), S. NANCEY (13), S. VIENNOT (14), E. LOUIS (15), M. SVRCEK (2) / [1] CHU Liege, Liège, Belgium, gastroenterology, [2] Hospital Saint Antoine, , Equatorial Guinea, Pathology, [3] CHU Lille, France, Gastroenterology, [4] CHU Bordeaux, , France, Gastroenterology, [5]

institut des MICI, , France, Gastroenterology, [6] CHU Amiens, France, Gastroenterology, [7] Hospital Saint Louis, , France, Gastroenterology, [8] Kremelin Bicêtre, , France, Gastroenterology, [9] CHU Montpellier, , France, Gastroenterology, [10] University Hospital Ghent (UZ Gent), Gent, Belgium, Gastroenterology, [11] Hospital Saint Antoine, Equatorial Guinea, Gastroenterology, [12] CHU Nantes, France Gastroenterology, [13] CHU Lyon, Lyon, France, Gastroenterology, [14] Clinique de l'Alma, , France, Gastroenterology, [15] CHU Liege, Liège, Belgium, Gastroenterology

14:55 **158** **I 04** **The Histo-endoscopic Spectrum in Ulcerative Colitis reveals a Distinct Mucosal Transcriptome for Histo-endoscopic Remission.**
M. LENFANT (1), G. DE HERTOOGH (1), J. SABINO (1), B. VERSTOCKT (1), M. FERRANTE (1), S. VERSTOCKT (2), S. VERMEIRE (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology and Hepatology, [2] KUL - University of Leuven, Leuven, Belgium, Chronic Diseases, Metabolism and Ageing

15:05 **Invited Lecture: From white light to advanced and precision endoscopy in IBD.**
Marietta Iacucci (Cork, Ireland)

15:30-16:00 Coffee break

Session 2: **From the bed back to the bench.**

Moderators : Triana Lobaton (UGent), Sophie Vieujean (CHU Liège)

16:00 **80** **I 05** **Mucin mRNA isoform signatures as potential novel biomarkers to evaluate disease status in patients with inflammatory bowel diseases.**
W. ARRAS (1), B. OOSTERLINCK (1), A. JAUREGUI AMEZAGA (2), M. SOMERS (2), E. MACKEN (2), J. DE MAN (1), B. DE WINTER (1), A. SMET (1) / [1] University of Antwerp, Antwerp, Belgium, Laboratory of experimental medicine and pediatrics, [2] Antwerp University Hospital, Edegem, Belgium, Gastro-entérologie en hepatologie

16:10 **199** **I 06** **The lipidome of creeping fat in Crohn's disease points towards a harmful microenvironment.**
S. VERSTOCKT (1), J. DEHAIRS (2), F. VANDERHOYDONC (2), B. KE (1), I. DE GREEF (1), J. SABINO (3), M. FERRANTE (3), G. BISLENGHI (4), A. D'HOORE (4), J. SWINNEN (2), B. VERSTOCKT (3), S. VERMEIRE (3) / [1] Translational Research Center for Gastrointestinal Disorders (TARGID), KULeuven, Leuven, Belgium, Department of Chronic Diseases and Metabolism (CHROMETA), [2] KUL - University of Leuven, Leuven, Belgium, Department of Oncology, [3] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [4] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Abdominal Surgery

16:20 **Invited Lecture: How preclinical models (can) inform therapeutic development in IBD.**

Gianluca Matteoli (Leuven, Belgium)

16:40 164 I 07 **Study of the role of the epithelium in the initiation and progression of intestinal fibrosis in Ulcerative Colitis.**

M. STEPNIAK (1), P. ADAM (2), C. SALÉE (3), J. LOLY (2), S. VIEUJEAN (2), C. REENAERS (2), F. FONZÉ (2), C. MASSOT (2), C. COIMBRA GARCIA MARQUES (4), E. DECKER (4), N. BLÉTARD (4), P. DELVENNE (4), S. SPECA (5), E. LOUIS (2), M. MEUWIS (2) / [1] University of Liege, Liège, Belgium, Translational Gastroenterology, [2] Liege University Hospital, Liege, Belgium, Gastroenterology, [3] Liege University Hospital, Liege, Belgium, Gastroen, [4] Liege University Hospital, Liege, Belgium, Anatomopathology, [5] University of Lille, Inserm, CHU Lille, , France, Infinite unit

16:50 157 I 08 **TWIST1-mediated FAP fibroblasts drives fibrosis in Crohn's disease.**

B. KE (1), S. ABDURAHIMAN (1), B. VERSTOCKT (1), F. BISCU (1), G. ZANELLA (1), A. ZOUZAF (1), L. VAN BAARLE (1), V. DE SIMONE (1), M. STAKENBORG (1), S. SANTHOSH (1), S. VERSTOCKT (1), G. DE HERTOIGH (2), S. VERMEIRE (1), G. MATTEOLI (1) / [1] Translational Research Center for Gastrointestinal Disorders (TARGID), KULeuven, Leuven, Belgium, Department of Chronic Diseases and Metabolism, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Pathology

17:00-17:45 **Satellite symposium ABBVIE**

Remo Pannacione



Thursday February 1, 2024

08:15-08:45 **Satellite symposium CELLTRION**

Erwin Dreesen and Bram Verstockt

Session 3: **X is greater than the sum of its parts, a multidisciplinary view.**

Moderators: Catherine Reenaers (Liège), Clara Caenepeel (ZOL Genk)

09:00 **Invited Lecture:** The multidisciplinary IMID clinic of the future.
Triana Lobaton and Gaëlle Varkas (UZ Gent)

09:25 **170 I 09** **Quality of care for patients with inflammatory bowel diseases: development and validation of a Belgian quality indicator set.**
L. FIERENS (1), C. LIEFFERINCKX (2), J. SABINO (3), E. DE DYCKER (3), V. WAMBACQ (2), K. VANHAECHT (4), F. RADEMAKERS (5), P. BOSSUYT (6), F. BAERT (7), D. BAERT (8), M. FERRANTE (3) / [1] Kliniek Sint-Jan, Brussel, Belgium, Translational Research in Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism (CHROMETA), [2] CUB Hôpital Erasme, Belgium, Department of gastroenterology, [3] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [4] KUL - University of Leuven, Leuven, Belgium, Department of Public Health and Primary Care, [5] KUL - University of Leuven, Leuven, Belgium, Faculty of Medicine, [6] Imelda General Hospital, , Belgium, Imelda GI Clinical Research Centre, [7] AZ Delta, Roeselare, Belgium, Department of Gastroenterology, [8] AZ Maria Middelaers, Ghent, Belgium, Department of Gastroenterology

09:35 **221 I 10** **Patient Preferences for Inflammatory Bowel Disease Treatments: A European Survey using a Discrete Choice Experiment.**
E. SCHOEFS (1), R. JANSSENS (1), Á. GUTIÉRREZ-VARGAS (2), M. FERRANTE (3), J. SABINO (3), B. VERSTOCKT (3), L. AVEDANO (4), M. DE ROCCHIS (4), M. SAJAK-SZCZERBA (4), R. SALDAÑA (4), N. STRAETEMANS (5), M. VANDEBROEK (2), S. VERMEIRE (3), I. HUYS (1) / [1] KUL - University of Leuven, Leuven, Belgium, Department of Pharmaceutical and Pharmacological Sciences, [2] KUL - University of Leuven, Leuven, Belgium, Faculty of Economics and Business, [3] University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium, Department of Gastroenterology and Hepatology, [4] EFCCA, , Belgium, European Federation of Crohn's & Ulcerative Colitis Associations, [5] AZ Vesalius Tongeren, Tongeren, Belgium, Department of Gastroenterology

09:45 **195 I 11** **Early biological use in a Belgian, prospective inception cohort of patients with inflammatory bowel disease: the PANTHER cohort (BIRD best abstract 2024)**
S. VERSTOCKT (1), E. GLORIEUS (2), M. DE WOLF (3), M. LENFANT (1), M. BARBARACI (3), J. SABINO (4), M. FERRANTE (4), J. GELDOLF (2), B. VERSTOCKT (4), D. LAUKENS (5), I. CLEYNEN (6), L. VANDERMEULEN (3), T. LOBATON (2), S. VERMEIRE (4) / [1] Translational Research Center for Gastrointestinal Disorders (TARGID), KULeuven, Leuven, Belgium, Department of Chronic Diseases and Metabolism (CHROMETA), [2] University Hospital of Ghent, , Belgium, Department of Gastroenterology,

[3] University Hospital of Brussels, Brussels, Belgium, Department of

Gastroenterology and Hepatology, [4] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [5] Ghent University, Ghent, Belgium, Department of Internal Medicine and Pediatrics, [6] KUL – University of Leuven, Leuven, Belgium, Department of Human Genetics

09:55 **224** | **12** **Age-Related Patterns in Biological Therapy Use and Surgery Among IBD Patients: Insights from the Belgian PANTHER cohort.**

J. CELIS (1), M. TRUYENS (2), S. VERSTOCKT (3), E. GLORIEUS (4), M. DE WOLF (5), M. LENFANT (3), M. BARBARACI (5), J. SABINO (3), M. FERRANTE (3), J. GELDOLF (4), B. VERSTOCKT (6), D. LAUKENS (7), I. CLEYNEN (8), L. VANDERMEULEN (5), S. VERMEIRE (9), T. LOBATON (4) / [1] Universiteit Gent, Gent, Belgium, Internal medicine and pediatrics, [2] Ghent University Hospital, Ghent, Belgium, Department of Gastroenterology, [3] KUL - University of Leuven, Leuven, Belgium, Department of Chronic Diseases and Metabolism (CHROMETA), [4] University Hospital of Ghent, , Belgium, Department of Gastroenterology, [5] University Hospital of Brussels, Brussels, Belgium, Department of Gastroenterology, [6] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [7] Ghent University, Ghent, Belgium, department of Internal Medicine and Pediatrics, [8] KUL – University of Leuven, Leuven, Belgium, Department of Human Genetics, [9] KUL - University of Leuven, Leuven, Belgium, Department of Gastroenterology and Hepatology

10:05 **Invited Lecture:** The multidisciplinary IMID clinic of the future.
Gabriele Bislenghi and Bram Verstockt (UZ Leuven)

10:30-11:10 Coffee break

Session 4: **Breaking the ceiling.**

Moderators: Aranzazu Jauregui Amezaga (Antwerp), Anneline Cremer (Erasme)

11:10 **105** | **13** **Uptake and outcome of treatment with the GLP-2 analogue teduglutide for short bowel syndrome with intestinal failure in Belgium.**

T. VANUYTSEL (1), A. BALLARIN (2), H. DE SCHEPPER (3), K. GEBOERS (1), A. HADEFI (2), D. HERMANS (4), I. HOFFMAN (5), K. HUYSENTRUYT (6), N. LAUWERS (1), V. ELS (7), C. VERCAUTEREN (8), L. WAUTERS (1), M. ARVANITAKIS (2) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Leuven Intestinal Failure and Transplantation (LIFT), [2] Hopital Erasme, ULB, Belgium, Gastroenterology, [3] UZA, Universitair Ziekenhuis Antwerpen, Edegem, Belgium, Gastroenterology, [4] UCL Saint Luc, Brussels, Belgium, Pediatric Gastroenterology, [5] University Hospitals Leuven

(UZLeuven), Leuven, Belgium, Pediatric Gastroenterology, [6] UZ Brussel, Brussels, Belgium, Pediatric Gastroenterology, [7] UZA, Universitair Ziekenhuis Antwerpen, Edegem, Belgium, Pediatric Gastroenterology, [8] UZ Brussel, Brussels, Belgium, Pediatric Surgery

11:20 174 I 14 **Radiation exposure in patients with inflammatory bowel disease in a Belgian tertiary referral centre.**

T. JORISSEN (1), L. FIERENS (2), H. BOSMANS (3), B. VERSTOCKT (4), J. SABINO (4), S. VERMEIRE (4), D. VANBECKEVOORT (3), M. FERRANTE (4) / [1] KUL - University of Leuven, Leuven, Belgium, Faculty of Medicine, [2] KUL - University of Leuven, Leuven, Belgium, Translational Research in Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism (CHROMETA), [3] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Radiology, [4] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology

11:30 **Invited Lecture:** Combination therapies, road to success?
Remo Panaccione (Calgary, Canada)

11:55 171 I 15 **Limited long-term efficacy of corticosteroids in microscopic colitis emphasizing the need for advanced therapies**

T. Taelman (1), S. Vermeire (1), M. Ferrante (1), J. Sabino (1), B. Verstockt (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology

12:05 127 I 16 **Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort.**

B. Verstockt (1), T. Taelman (1), S. Vavricka (2), Y. Zabana (3), M. Lenfant (1), G. Maicagne (4), M. Maillard (5), E. Savarino (6), N. Teich (7), V. Kiudelis (8), J. De la Revilla Negro (9), D. Ribaldone (10), M. Barreiro-de Acosta (11), S. Wildt (12), P. Rivière (13), M. Fumery (14), M. Truyens (15), A. Amiot (16), J. Marsal (17), A. Levartovsky (18), S. Vieujean (19), M. Somers (20), A. Cremer (21), I. Lutakov (22), N. Cohen (23), S. Dewit (24), L. Bajer (25), J. Rahier (26), A. Backman (27), S. Nancey (28), T. Choden (29), J. Van Dongen (30), A. Münch (31), M. Julsgaard (32) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [2] University Hospital Zürich, Zürich, Switzerland, Department of Gastroenterology and Hepatology, [3] Hospital Universitari Mútua Terrassa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), , Spain, Department of Gastroenterology, [4] Centre Hospitalier de Marne-la Vallée, Jossigny, France, Hepatogastroenterology Unit, [5] Lausanne Digestive Disease Center, Lausanne, Switzerland, Lausanne Digestive Disease Center, [6] University of Padua, Padua, Italy, Department of Surgery, Oncology and Gastroenterology, [7] Internistische Gemeinschaftspraxis, Leipzig, Germany, Gastroenterology, [8] Hospital of Lithuanian University of Health Sciences, Kaunas,

Lithuania, Department of Gastroenterology, [9] Addenbrookes

Hospital, Cambridge, United Kingdom (the), Department of Gastroenterology, [10] University of Turin, , Italy, Department of Medical Sciences, [11] University Hospital Santiago De Compostela CHUS, Santiago De Compostela, Spain, Department of Gastroenterology- IBD Unit, [12] Hvidovre Hospital, University Hospital of Copenhagen, Copenhagen, Denmark, Gastrounit, [13] CHU Bordeaux, , France, Service d'hépatogastroentérologie et oncologie digestive, [14] University Hospital of Amiens, France, Department of gastroenterology, [15] University Hospital of Ghent, Belgium, Department of Gastroenterology, [16] Bicetre university hospital, Paris Saclay university, le Kremlin Bicêtre, France, Department of gastroentérologie, [17] Skåne University Hospital, Sweden, Department of Gastroenterology, [18] Sheba Medical Center, Tel Aviv, Israel, Department of Gastroenterology, [19] University Hospital CHU of Liège, , Belgium, Hepato-Gastroenterology and Digestive Oncology, [20] Antwerp University Hospital, Edegem, Belgium, Department of Gastroenterology and Hepatology, [21] Erasme University Hospital - Université Libre de Bruxelles (ULB), Bruxelles, Belgium, Department of Gastroenterology and Hepatology, [22] University Hospital "Queen Joanna-ISUL" Sofia, Sofia, Bulgaria, Clinical Center of Gastroenterology, [23] Tel Aviv Medical Center, Tel Aviv, Israel, IBD Center, Department of Gastroenterology and Liver Diseases, [24] Noorderhart Mariaziekenhuis, Pelt, Belgium, Department of Gastroenterology, [25] Institute for Clinical and Experimental Medicine, Prague, Czech Republic (the), Department of Gastroenterology and Hepatology, [26] Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium, Department of Gastroenterology and Hepatology, [27] Ersta Hospital, Stockholm, Sweden, Department of Internal Medicine, [28] Lyon-Sud hospital, Hospices Civils de Lyon, Lyon, France, Department of Gastroenterology, [29] University of Chicago Medicine, Chicago, United States (the), Inflammatory Bowel Disease Center, [30] AZ Sint Maarten, Mechelen, Belgium, Department of Gastroenterology, [31] Linköping University, Linköping, Sweden, Department of Gastroenterology and Hepatology, [32] Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, Department of Hepatology and Gastroenterology

12:15-13:00 **Satellite symposium Elli Lilly**

Marietta Iacucci and Lieven Pouillon

Abstracts selected for poster presentation:

- 25 I 17 3D bioprinting of gelatin derivatives: towards novel small intestinal in vitro Models.
L. MAES (1), A. SZABÓ (2), J. VAN HAEVERMAETE (2), I. GEURS (2), K. DEWETTINCK (3), S. VAN VLIERBERGHE (2), D. LAUKENS (1) / [1] Ghent University, Ghent, Belgium, Department of Internal Medicine and Pediatrics, [2] Ghent University, Ghent, Belgium, Department of Organic and Macromolecular Chemistry, [3] Ghent University, Ghent, Belgium, Department of Food Technology, Safety and Health
- 46 I 18 FOod Additives on the Mucosal barrier study (FOAM): effect of dietary emulsifiers on inflammation, permeability, and the microbiome: preliminary results.
J. WELLENS (1), J. VANDERSTAPPEN (1), S. HOEKX (1), E. VISSERS (2), M. LUPPENS (2), J. RAES (3), B. VERSTOCKT (1), M. FERRANTE (1), K. VERBEKE (2), C. MATTHYS (4), S. VERMEIRE (1), J. SABINO (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology and Hepatology, [2] KUL - University of Leuven, Leuven, Belgium, Department of Chronic Diseases, Metabolism and Ageing – Translational Research Center for Gastrointestinal Disorders, [3] Rega Institute- KU Leuven, Leuven, Belgium, Microbiology- Immunology and Transplantation Department, [4] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Endocrinology
- 47 I 19 An emulsifier-free diet is acceptable, feasible and can be adhered to by healthy volunteers.
J. WELLENS (1), M. LUPPENS (2), S. HOEKX (3), J. VANDERSTAPPEN (3), L. VAN ELST (2), E. VISSERS (2), M. FERRANTE (3), B.VERSTOCKT (3), K. VERBEKE (2), C. MATTHYS (4), S. VERMEIRE (3), J. SABINO (3) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [2] KUL - University of Leuven, Leuven, Belgium, Department of Chronic Diseases, Metabolism and Ageing - Translational Research Center for Gastrointestinal Disorders, [3] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology and Hepatology, [4] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Endocrinology
- 66 I 20 Lipopolysaccharide-Binding Protein (LBP) in Crohn's Disease (CD) Patients: A Promising Non-Invasive Biomarker Monitoring Disease Activity.
L. TORIS (1), C. MINSART (2), C. HUSSON (1), D. FRANCHIMONT (2), C. LIEFFERINCKX (2) / [1] ULB, Brussels, Belgium, Laboratory of Experimental Gastroenterology, [2] Hopitaux Universitaires de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Belgium, Dept. Gastroenterology, Hepato-Pancreatology and Digestive Oncology
- 72 I 21 VARIETY BEACH study: Real-world treatment patterns for vedolizumab

intravenous and subcutaneous maintenance dosing observed over 1 year

in studies from Belgium, Austria and Switzerland.

E. LOUIS (1), G. NOVACEK (2), P. HRÚZ (3), C. HÖGENAUER (4), S. VAVRICKA (5), A. MOSCHEN (6), L. BIEDERMANN (7), C. MÄCHLER (8), B. STEMBERGER (9), G. VAN GASSEN (10), F. BAERT (11) / [1] CHU de Liège, Liège, Belgium, Gastro-enterologie, [2] Medical University of Vienna, Vienna, Austria, Internal Medicine, [3] Clarunis Universitäres Bauchzentrum, Basel, Switzerland, Gastro-enterology, [4] Medical University Graz, Graz, Austria, Gastro-enterology, [5] University Hospital Zürich, Zürich, Switzerland, Gastro-enterology and hepatology, [6] Johannes Kepler University, Linz, Austria, Internal Medicine, [7] University Hospital, Zurich, Switzerland, Gastro-enterology and hepatology, [8] Takeda Pharma AG, Glattpark, Switzerland, Medical Affairs, [9] Takeda Ges.m.b.H, Wien, Austria, Medical Affairs, [10] Takeda Belgium, Brussels, Belgium, Medical Affairs, [11] AZ Delta, Roeselare, Belgium, Gastro-enterology

- 74 I 22 Reduced parenteral support needs with the novel long-acting GLP-2 analog apraglutide in patients with short bowel syndrome with intestinal failure and colon in continuity at 52 weeks.
A. VERBIEST (1), M. KROGH HVISTENDAHL (2), F. BOLOGNANI (3), C. LI (3), N. N. YOUSSEF (4), P. BEKKER JEPPESEN (2), F. JOLY (5), T. VANUYTSEL (1) / [1] KUL - University of Leuven, Leuven, Belgium, Translational Research Center for Gastrointestinal Disorders (TARGID), [2] Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, Department of Intestinal Failure and Liver Diseases, [3] VectivBio , Basel, Switzerland, Clinical Development, [4] VectivBio, Basel, Switzerland, Medical Affairs, [5] Hopital Beaujon (AP-HP), France, Centre for Intestinal Failure, Department of Gastroenterology and Nutritional Support
- 76 I 23 STRIDE-II recommendations in routine IBD patient management: a nested study of the Belgian population within the real-world international multicentre IBD-PODCAST study.
B. VERSTOCKT (1), J. SCHREVEN (2), A. COLARD (3), F. D'HEYGERE (4), B. STRUBBE (5), J. VAN DONGEN (6), C. LEITNER (7), B. GILLON (2), L. GHYS (2), D. FRANCHIMONT (8) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology and hepatology, [2] Abbvie, Wavre, Belgium, Medical Affairs, [3] Clinique Mont Legia - CHC Groupe Santé, Liège, Belgium, Gastroenterology , [4] AZ Groeninge, Kortrijk, Belgium, Internal Medicine/Gastroenterology, [5] AZ Sint-Lucas, Ghent, Belgium, Gastroenterology and hepatology, [6] AZ Sint Maarten, Mechelen, Belgium, Gastroenterology , [7] AbbVie Switzerland, Cham, Switzerland, Medical Affairs, [8] Hopital Erasme, ULB, Belgium, Gastroenterology
- 78 I 24 Clinical parameters of STRIDE-II leading to adjustment in monitoring or therapy in IBD patients – results from the Belgian cohort of the IBD-PODCAST study.
B. VERSTOCKT (1), J. SCHREVEN (2), A. COLARD (3), F. D'HEYGERE (4), B. STRUBBE (5), J. VAN DONGEN (6), C. LEITNER (7), J. MORRENS (2), L. GHYS (2), D. FRANCHIMONT (8) / [1] University Hospitals Leuven

(UZLeuven), Leuven, Belgium, Gastroenterology and hepatology,

[2] Abbvie, Wavre, Belgium, Medical Affairs, [3] Clinique Mont Legia – CHC Groupe Santé, Liège, Belgium, Gastroenterology , [4] AZ Groeninge, Kortrijk, Belgium, Internal Medicine/Gastroenterology, [5] AZ Sint-Lucas, Ghent, Belgium, Gastroenterology and hepatology, [6] AZ Sint Maarten, Mechelen, Belgium, Gastroenterology , [7] AbbVie Switzerland, Cham, Switzerland, Medical Affairs, [8] Hopital Erasme, ULB, Belgium, Gastroenterology

- 83 I 25 Distinct blood protein profiles associated with ileal and colonic ulcers in Crohn's disease.
N. PIERRE (1), V. HUYNH-THU (2), D. BAIWIR (3), S. VIEUJEAN (1), E. BEQUET (1), C. REENAERS (4), C. VAN KEMSEKE (4), C. SALÉE (1), C. MASSOT (1), M. FLÉRON (3), G. MAZZUCHELLI (5), L. TRZPIOT (5), G. EPPE (5), E. DE PAUW (5), E. LOUIS (1), M. MEUWIS (1) / [1] University of Liege, Liege, Belgium, Laboratory of Translational Gastroenterology, GIGA institute, [2] University of Liege, Liege, Belgium, Department of Electrical Engineering and Computer Science, [3] University of Liege, Liege, Belgium, GIGA Proteomics Facility, [4] Liege University Hospital, Liege, Belgium, Hepato-Gastroenterology and Digestive Oncology Department, [5] University of Liege, Liege, Belgium, Laboratory of Mass Spectrometry, MoISys Research Unit
- 94 I 26 Safety and effectiveness of vedolizumab and ustekinumab in inflammatory bowel disease patients after liver transplantation for primary sclerosing cholangitis: results from an ECCO-confer case series.
T. HOLVOET (1), E. BRUSSELLE (2), B. VERSTOCKT (3), M. LENFANT (3), M. JULSGAARD (4), D. DROBNE (5), A. THAKOR (6), H. GORDON (7), T. MOLNAR (8), E. SAVARINO (9), D. RIBALDONE (10), P. MIHELLER (11), S. VIEUJEAN (12), I. CANDEL (13), L. MENCHEN (14), D. BETTENWORTH (15), P. EDER (16), A. ISSACHAR (17), T. LOBATON (2) / [1] Vitaz, Sint-Niklaas, Belgium, Gastroenterology, [2] Ghent University Hospital, Ghent, Belgium, Gastroenterology, [3] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology, [4] Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, Hepatology and Gastroenterology, [5] University Medical Centre Ljubljana, Ljubljana, Slovenia, Gastroenterology, [6] Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (the), Gastroenterology, [7] Royal London Hospital, London, United Kingdom (the), Gastroenterology, [8] University of Szeged, Szeged, Hungary, Gastroenterology, [9] University of Padua, Padua, Italy, Gastroenterology, [10] University of Turin, , Italy, Gastroenterology, [11] Semmelweis University, Budapest, Hungary, Gastroenterology, [12] CHU Liege, Liège, Belgium, Gastroenterology, [13] Udaondo's Hospital, Buenos Aires, Argentina, Gastroenterology, [14] Hospital General Universitario "Gregorio Marañón, Madrid, Spain, Gastroenterology, [15] Münster University Hospital, Münster, Germany, Clinical Medicine, [16] Poznan University, Poznan, Poland, Gastroenterology, Dietetics and Internal Medicine, [17]

- 116 I 27 Outcomes in patients stopping biologic during the first trimester of pregnancy: a retrospective monocentric study.
L. MONIN (1), C. REENAERS (1), S. GRANDFILS (2), P. LATOUR (1), C. VAN KEMSEKE (1), S. KROPP (1), E. LOUIS (1), S. VIEUJEAN (1) / [1] CHU Liege, Liège, Belgium, Hepato-Gastroenterology and Digestive Oncology, [2] CHU Liege, Liège, Belgium, Gynecology
- 124 I 28 No difference in progression of disability 2 years after stopping infliximab or immunosuppressant vs. continuing combination therapy in patients with CD in sustained steroid-free remission: a subanalysis of SPARE.
S. VIEUJEAN (1), K. DESSEAUX (2), D. LAHARIE (3), J. SATSANGI (4), N. DING (5), B. SIEGMUND (6), G. D'HAENS (7), L. PICON (8), P. BOSSUYT (9), L. VUITTON (10), P. IRVING (11), S. VIENNOT (12), C. LAMB (13), R. POLLOK (14), F. BAERT (15), M. NACHURY (16), M. FUMERY (17), C. GILLETTA (18), M. RESCHE-RIGON (19), Y. BOUHNIC (20), J. COLOMBEL (21), E. HERTERVIG (22), E. LOUIS (1) / [1] University Hospital CHU of Liège, Belgium, Hepato-Gastroenterology and Digestive Oncology, [2] INSERM U717 Saint-Louis Hospital, France, Department of statistics, [3] Hôpital Haut-Lévêque– Université de Bordeaux, , France, Service d'Hépatogastroentérologie et oncologie digestive CHU de Bordeaux, [4] John Radcliffe Hospital, , United Kingdom (the), Translational Gastroenterology Unit, Nuffield Department of Medicine, [5] St Vincent's Hospital Melbourne, Australia, Department of Gastroenterology, [6] Universitätsmedizin Berlin, Germany, Medical Department, Division of Gastroenterology, Infectious Diseases and Rheumatology, Charité, [7] Amsterdam University Medical Centres, Netherlands (the), Department of Gastroenterology and Hepatology, [8] Hôpital Trousseau, France, Hépatogastro-Entérologie, [9] Imelda General Hospital, Belgium, Imelda GI Clinical Research Center, [10] Besançon University Hospital, France, Department of Gastroenterology, [11] Guy's and St Thomas' NHS Foundation Trust, United Kingdom (the), IBD Unit, Department of Gastroenterology, [12] University Hospital of Caen, France, Department of Gastroenterology, [13] Newcastle University, United Kingdom (the), Translational & Clinical Research Institute, [14] St Georges University Hospital, United Kingdom (the), Gastroenterology, [15] AZ Delta, Belgium, Department of Gastroenterologie, [16] University of Lille, Inserm, CHU Lille, France, U1286 - INFINITE - Institute for Translational Research in Inflammation, [17] University Hospital of Amiens, , France, Department of Gastroenterology, [18] University Hospital of Toulouse Rangueil, France, Department of Gastroenterology and Pancreatology, [19] Hopital Saint Louis, France, Université de Paris, ECSTRRA - CRESS UMR1153, INSERM and SBIM, AP-HP, [20] Beaujon Hospital, APHP, Paris Cité University, , France, Department of Gastroenterology, [21] Icahn School of Medicine at Mount Sinai, United States (the), Department of Gastroenterology, [22] Skåne University Hospital, , Sweden, Department of Gastroenterology

- 133 I 29 Dietary emulsifier K-carrageenan does not directly affect intestinal permeability in organoid-derived epithelial monolayers from patients with Crohn's disease.
E. VISSERS (1), K. ARNAUTS (1), L. GIORIO (1), W. ZADORA (2), J. WELLENS (1), B. VERSTOCKT (3), M. FERRANTE (3), S. VERMEIRE (3), C. MATTHYS (4), J. SABINO (3) / [1] KUL - University of Leuven, Leuven, Belgium, Department of Chronic Diseases and Metabolism (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), [2] KUL - University of Leuven, Leuven, Belgium, Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, [3] University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium, Department of Gastroenterology and Hepatology, [4] University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium, Department of Endocrinology
- 153 I 30 Reduction of mucosal (active) eosinophils, B cells and T cells after vedolizumab therapy in patients with ulcerative colitis.
I. JACOBS (1), J. CREMER (1), M. FERRANTE (2), J. SABINO (2), S. VERMEIRE (2), C. BREYNAERT (2), T. VANUYTSEL (2), B. VERSTOCKT (2) / [1] KUL – University of Leuven, Leuven, Belgium, Department of Microbiology, Immunology and Transplantation, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology
- 161 I 31 Unraveling the transcriptional dynamics of enteric glial cells in intestinal homeostasis and disease.
S. SANTHOSH (1), L. VAN BAARLE (1), V. DE SIMONE (1), S. ABDURAHIMAN (1), A. ZOUZAF (1), M. HAO (2), L. STAMP (2), G. MATTEOLI (1) / [1] Translational Research Center for Gastrointestinal Disorders (TARGID), KULeuven, Leuven, Belgium, Department of Chronic Diseases and Metabolism, [2] University of Melbourne, Parkville, Australia, Department of Anatomy and Physiology
- 162 I 32 JAKne: JAK inhibitor associated acne, a real-life single-center experience.
E. DE DYCKER (1), S. VERMEIRE (1), M. FERRANTE (1), T. LAMBRECHTS (1), A. PAPS (1), P. GEENS (1), E. LODDEWIJKX (1), J. SABINO (1), T. HILLARY (2), B. VERSTOCKT (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Dermatology
- 185 I 33 Simplified MARIA score does not predict long-term outcomes in Crohn's disease patients undergoing modified side-to-side strictuoplasty for extensive ileitis.
I. DE GREEF (1), G. BISLENGHI (2), M. LENFANT (3), S. VERSTOCKT (3), I. TERRASSON (2), B. VERSTOCKT (4), J. SABINO (4), M. FERRANTE (4), D. VANBECKEVOORT (5), A. D'HOORE (2), S. VERMEIRE (4) / [1] KUL –

(CHROMETA), [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Abdominal Surgery, [3] KUL - University of Leuven, Leuven, Belgium, Department of Chronic Diseases and Metabolism, [4] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [5] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Radiology

- 220 I 34 The comparative effectiveness and safety of different biologics in young (<60 years) versus elderly (≥ 60 years) patients with IBD: results from a real-world experience at a Belgian tertiary centre.
L. DEROO (1), M. TRUYENS (1), J. GELDOF (1), S. AKHAYAD (1), G. DEWITTE (1), E. GLORIEUS (1), T. LOBATON (1) / [1] University Hospital Ghent (UZ Gent), Ghent, Belgium, Gastroenterology and Hepatology